Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC)-MedSci.cn

Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC)

Rini, BI; Atkins, MB; Escudier, BJ; Hutson, TE; Koralewski, P; McDermott, DF; Pal, SK; Needle, MN; Porta, C

JOURNAL OF CLINICAL ONCOLOGY, 2017; 35 ( ):

科室
- - 订阅+
  - 更多科室
工具
服务